- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Marconi HCP appoints prez, cuts new deals
Louis H. (Larry) Miller has been promoted to president of Marconi Health Care Products. Miller, who was previously vice president and general manager of HCP, has become only the third president in HCP’s history. Miller will emphasize e-business
Louis H. (Larry) Miller has been promoted to president of Marconi Health Care Products. Miller, who was previously vice president and general manager of HCP, has become only the third president in HCP’s history. Miller will emphasize e-business initiatives revolving around the imaging distributor’s Web site, marconihcp.com.
In other news, HCP has signed a three-year agreement with Broadlane, which specializes in the delivery of supply chain services to the healthcare industry. The contract extends an existing contract and contains two one-year renewal options. The deal is potentially worth more than $30 million in annual sales. HCP has also entered into a relationship with Deus Technologies to distribute that company’s Rapid-Screen RS-2000. The system uses computer-aided detection to identify regions possibly associated with early-stage lung cancer.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
